Ambrx

Ambrx is a biopharmaceutical company that discovers and develops antibody-drug conjugates and immuno-oncology therapies for cancer diseases. Read more

Feng Tian's photo - Chairman & CEO of Ambrx

Chairman & CEO

Feng Tian

CEO Approval Rating

86/100

Founded:

2003

Status:

PublicSubsidiary of WuXi AppTec Co., Ltd.NASDAQAMBX

AMBRX TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

AVEO is Ambrx's biggest rival. AVEO was founded in Boston, Massachusetts} in 2001. Like Ambrx, AVEO also competes in the Biotechnology sector. Compared to Ambrx, AVEO generates $7.2M more revenue.

Celldex is Ambrx's #2 rival. Celldex's headquarters is in Hampton, New Jersey, and was founded in 1983. Like Ambrx, Celldex also competes in the Biotechnology space. Celldex generates ∞% of Ambrx's revenue.

Almac is Ambrx's #3 competitor. Almac was founded in 2002 in Craigavon, England. Almac operates in the Health Care Technology industry. Almac generates $862.5M more revenue than Ambrx.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Surface Oncology a competitor of Ambrx?

Ambrx Quarterly and Annual Revenue

Coming soon for Ambrx!

Annual Revenue

Ambrx Acquisitions

No recent acquisitions found related to Ambrx

Ambrx Funding History

Since Ambrx was founded in 2003, it has participated in 9 rounds of funding. In total Ambrx has raised $438.2M. Ambrx's last funding round was on Nov 2020 for a total of $200.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Private Equity Round
Nov 2020
$200M
Debt - PPP (CARES Act)
May 2020
$1M - $2M
Private Equity Round
Aug 2016
$45M
IPO
May 2014
$86.3M

Series D
Mar 2009
$10M

Since Ambrx was founded in 2003, it has participated in 9 rounds of funding. In total Ambrx has raised $438.2M. Ambrx's last funding round was on Nov 2020 for a total of $200.0M

Ambrx Investments

No recent investments found related to Ambrx

Ambrx News

December 10, 2020MarketScreener

Ambrx Presents Phase 1 Trial Data Update and Phase 2/3 Clinical Trial in Progress for Lead Program ARX788 at the 2020 San Antonio Breast Cancer Symposium

(marketscreener.com) SAN DIEGO, Dec. 10, 2020 /PRNewswire/ -- Ambrx Inc., a clinical-stage biopharmac... See more »
November 27, 2020Global Legal Chronicle

Ambrx Inc.'s US$200 Million Crossover Financing Round

Wilson Sonsini Goodrich & Rosati advised WuXi AppTec Co. on the deal. Ambrx Inc., a portfolio company... See more »
November 24, 2020Endpoints News

After 5 quiet years, a former Scripps spinout raises $200M and announces plans to try again at an IPO

The first time San Diego biotech Ambrx tried to go public in 2014, they failed and the company's boar... See more »
November 23, 2020MedCity News

$200M investment to advance clinical programs for Ambrx

The San Diego-based biopharma firm has several oncology therapies in development and has partnered in... See more »
November 10, 2020socalTECH

Ambrx Raises $200M More

San Diego-based biopharmaceuticals developer Ambrx has raised $200M in a funding round, according to ... See more »
November 9, 2020FinSMEs

Ambrx Closes US$200M Crossover Financing Round

Ambrx Inc., a San Diego, CA-based clinical-stage...... See more »
January 17, 2020Global Legal Chronicle

Sino Biopharma's Collaboration with Ambrx, Inc

Sidley Austin LLP represented Ambrx, Inc in its collaboration with Sino Biopharma. Ambrx Inc., a clin... See more »

Ambrx Press Releases

September 29, 2016freePRnow

Therapeutics development for Lipodystrophy by companies -Pipeline Review,H2 2016

Lipodystrophy Pipeline Review, H2 2016 Global Markets Direct's, Lipodystrophy - Pipeline Review, H2 2... See more »
August 12, 2016PR Newswire

Global Cancer Immunotoxins Market & Clinical Pipeline Insight Report 2020 - Research and Markets

DUBLIN, August 12, 2016 /PRNewswire/ -- Research and Markets has announced the addition of the "Globa... See more »
July 21, 2016Business Wire

C-X-C Chemokine Receptor Type 4 Pipeline Review, H1 2016 - Research and Markets

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "C-X-C Chemokine Rece... See more »
June 2, 2016Business Wire

Global Obesity Pipeline Report H1 2016 - Review of 98 Companies & Drug Profiles - Research and Markets

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Obesity - Pipeline R... See more »
April 19, 2016Business Wire

Global Nasopharyngeal Cancer Pipeline Review 2016 - 17 Companies 32 Drug Profiles - Research and Markets

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Nasopharyngeal Cance... See more »
March 25, 2016PR Newswire

WuXi Biologics Congratulates Ambrx and ZMC for Successful Dosing of a Novel Antibody-Drug Conjugate in Australia

SHANGHAI, March 25, 2016 /PRNewswire/ -- WuXi Biologics, a wholly-owned subsidiary of WuXi AppTec (Wu... See more »

Social Media

Ambrx Headquarters

10975 North Torrey Pines Road

La Jolla, California92037

1-858-875-2400

Driving Directions »

Trending Companies

Ambrx Summary

ABOUT

Overview

Ambrx is a biopharmaceutical company that discovers and develops antibody-drug conjugates and immuno-oncology therapies for cancer diseases. Ambrx was founded in 2003. Ambrx's headquarters is located in La Jolla, California, USA 92037. It has raised 4...

CEO

Ambrx's Chairman & CEO, Feng Tian, currently has an approval rating of 86%. Ambrx's primary competitors are AVEO, Celldex & Almac.

Website

ambrx.com

Frequently Asked Questions about Ambrx

  1. When was Ambrx founded?

    Ambrx was founded in 2003
  2. Who is Ambrx's CEO?

    Ambrx's CEO is Feng Tian
  3. How much revenue does Ambrx generate?

    Ambrx generates $ < 1M in revenue
  4. How much funding does Ambrx have?

    Ambrx has historically raised $438.2M in funding
  1. Where is Ambrx's headquarters?

    Ambrx's headquarters is in La Jolla California, USA
  2. What sector does Ambrx operate in?

    Ambrx is in Biotechnology, Pharmaceuticals
  3. Who are Ambrx's competitors?

    Ambrx's top competitors are AVEO, Celldex, Almac